Erika F Brutsaert1, Mary L Biggs2, Joseph A Delaney2, Luc Djoussé3, John S Gottdiener4, Joachim H Ix5, Francis Kim2, Kenneth J Mukamal6, David S Siscovick7, Russell P Tracy8, Ian H de Boer2, Christopher R deFilippi4, Jorge R Kizer9. 1. Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: Erika.brutsaert@einstein.yu.edu. 2. University of Washington, Seattle, WA, USA. 3. Brigham and Women's Hospital, Boston, MA, USA. 4. University of Maryland Medical Center, Baltimore, MD, USA. 5. University of California San Diego, School of Medicine, La Jolla, CA, USA. 6. Beth Israel Deconness Medical Center, Boston, MA, USA. 7. New York Academy of Medicine, New York, NY, USA. 8. University of Vermont, Burlington, VT, USA. 9. Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract
INTRODUCTION: Natriuretic peptides have a well-recognized role in cardiovascular homeostasis. Recently, higher levels of B-type natriuretic peptide (BNP) have also been associated with decreased risk of diabetes in middle-aged adults. Whether this association persists into older age, where the pathophysiology of diabetes changes, has not been established, nor has its intermediate pathways. METHODS: We investigated the relationship between N-terminal (NT)-proBNP and incident diabetes in 2359 older adults free of cardiovascular disease or chronic kidney disease in the Cardiovascular Health Study. RESULTS: We documented 348 incident cases of diabetes over 12.6years of median follow-up. After adjusting for age, sex, race, body mass index, systolic blood pressure, anti-hypertensive treatment, smoking, alcohol use, and LDL, each doubling of NT-proBNP was associated with a 9% lower risk of incident diabetes (HR=0.91 [95% CI: 0.84-0.99]). Additional adjustment for waist circumference, physical activity, estimated glomerular filtration rate or C-reactive protein did not influence the association. Among putative mediators, HDL and triglycerides, adiponectin, and especially homeostasis model assessment of insulin resistance, all appeared to account for a portion of the lower risk associated with NT-proBNP. CONCLUSION: In older adults without prevalent cardiovascular or kidney disease, higher NT-proBNP is associated with decreased risk of incident diabetes even after adjustment for traditional risk factors. These findings suggest that the metabolic effects of natriuretic peptides persist late in life and offer a potential therapeutic target for prevention of diabetes in older people.
INTRODUCTION: Natriuretic peptides have a well-recognized role in cardiovascular homeostasis. Recently, higher levels of B-type natriuretic peptide (BNP) have also been associated with decreased risk of diabetes in middle-aged adults. Whether this association persists into older age, where the pathophysiology of diabetes changes, has not been established, nor has its intermediate pathways. METHODS: We investigated the relationship between N-terminal (NT)-proBNP and incident diabetes in 2359 older adults free of cardiovascular disease or chronic kidney disease in the Cardiovascular Health Study. RESULTS: We documented 348 incident cases of diabetes over 12.6years of median follow-up. After adjusting for age, sex, race, body mass index, systolic blood pressure, anti-hypertensive treatment, smoking, alcohol use, and LDL, each doubling of NT-proBNP was associated with a 9% lower risk of incident diabetes (HR=0.91 [95% CI: 0.84-0.99]). Additional adjustment for waist circumference, physical activity, estimated glomerular filtration rate or C-reactive protein did not influence the association. Among putative mediators, HDL and triglycerides, adiponectin, and especially homeostasis model assessment of insulin resistance, all appeared to account for a portion of the lower risk associated with NT-proBNP. CONCLUSION: In older adults without prevalent cardiovascular or kidney disease, higher NT-proBNP is associated with decreased risk of incident diabetes even after adjustment for traditional risk factors. These findings suggest that the metabolic effects of natriuretic peptides persist late in life and offer a potential therapeutic target for prevention of diabetes in older people.
Authors: O A Sanchez; D A Duprez; H Bahrami; C A Peralta; L B Daniels; J A Lima; A Maisel; A R Folsom; D R Jacobs Journal: Diabetes Metab Date: 2015-06-03 Impact factor: 6.041
Authors: Martin Magnusson; Amra Jujic; Bo Hedblad; Gunnar Engström; Margaretha Persson; Joachim Struck; Nils G Morgenthaler; Peter Nilsson; Christopher Newton-Cheh; Thomas J Wang; Olle Melander Journal: J Clin Endocrinol Metab Date: 2011-11-23 Impact factor: 5.958
Authors: Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan Journal: Circulation Date: 2004-02-10 Impact factor: 29.690
Authors: Allie S Carew; Rania A Mekary; Susan Kirkland; Olga Theou; Ferhan Siddiqi; Robin Urquhart; Michelle George; Chris Blanchard; Mary L Biggs; Luc Djoussé; Kenneth J Mukamal; Leah E Cahill Journal: Am J Clin Nutr Date: 2022-08-04 Impact factor: 8.472
Authors: Daniele Massera; Mary L Biggs; Marcella D Walker; Kenneth J Mukamal; Joachim H Ix; Luc Djousse; Rodrigo J Valderrábano; David S Siscovick; Russell P Tracy; Xiaonan Xue; Jorge R Kizer Journal: Diabetes Care Date: 2018-07-12 Impact factor: 19.112
Authors: Annette Masuch; Maik Pietzner; Martin Bahls; Kathrin Budde; Gabi Kastenmüller; Stephanie Zylla; Anna Artati; Jerzy Adamski; Henry Völzke; Marcus Dörr; Stephan B Felix; Matthias Nauck; Nele Friedrich Journal: Cardiovasc Diabetol Date: 2018-08-28 Impact factor: 9.951